SEC Info - Heart Test Laboratories, Inc.

SEC Info℠

Home

Help

Please Sign In

Heart Test Laboratories, Inc. – ‘8-K’ for 3/14/24

On: Thursday, 3/14/24, at 4:15pm ET · For: 3/14/24 · Accession #: 1213900-24-22613 · File #: 1-41422

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/14/24  Heart Test Laboratories, Inc.     8-K:2,9     3/14/24   12:267K                                   EdgarAgents LLC/FA

Current Report — Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     28K 
 2: EX-99.1     Press Release Dated March 14, 2024                  HTML     25K 
 7: R1          Cover                                               HTML     49K 
 9: XML         IDEA XML File -- Filing Summary                      XML     12K 
12: XML         XBRL Instance -- ea0201847-8k_hearttest_htm          XML     20K 
 8: EXCEL       IDEA Workbook of Financial Report Info              XLSX      8K 
 4: EX-101.DEF  XBRL Definitions -- hscs-20240314_def                XML     73K 
 5: EX-101.LAB  XBRL Labels -- hscs-20240314_lab                     XML    102K 
 6: EX-101.PRE  XBRL Presentations -- hscs-20240314_pre              XML     70K 
 3: EX-101.SCH  XBRL Schema -- hscs-20240314                         XSD     14K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               27±    36K 
11: ZIP         XBRL Zipped Folder -- 0001213900-24-022613-xbrl      Zip     27K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX:

i false i 0001468492 0001468492 2024-03-14 2024-03-14 0001468492 us-gaap:CommonStockMember 2024-03-14 2024-03-14 0001468492 HSCS:WarrantsMember 2024-03-14 2024-03-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM i 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): i March 14, 2024

i Heart Test Laboratories, Inc.

(Exact name of Registrant as Specified in Its Charter)

i Texas		i 001-41422		i 26-1344466
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

i 550 Reserve Street, Suite 360
i Southlake, i Texas		i 76092
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: i 682 i 237-7781

n/a

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

i ☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

i ☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

i ☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

i ☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
i Common Stock	i HSCS	The i Nasdaq Stock Market LLC
i Warrants	i HSCSW	The i Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company i ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. i ☐

Item 2.02 Results of Operations and Financial Condition.

On March 14, 2024, Heart Test Laboratories, Inc. (the “Company”) issued a press release providing information regarding the Company’s financial and operating results for the quarter ended January 31, 2024, and other business updates. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The information contained in Item 2.02 of this report and Exhibit 99.1 to this report shall not be deemed to be “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be incorporated by reference into any filings made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.		Description
99.1		Press Release dated March 14, 2024
Exhibit 104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	HEART TEST LABORATORIES, INC.

Date: March 14, 2024	By:	/s/ *Andrew Simpson*
	Name: Title:	Andrew Simpson President, Chief Executive Officer and Chairman of the Board of Directors

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

Filed on / For Period end:	3/14/24	10-Q, EFFECT
	1/31/24	10-Q, 8-K
		List all Filings

↑Top

Filing Submission 0001213900-24-022613 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)